Acyl-coenzyme A: Cholesterol Acyltransferase (ACAT) in cholesterol metabolism: From its discovery to clinical trials and the genomics era
The purification and cloning of the acyl-coenzyme A: cholesterol acyltransferase (ACAT)
enzymes and the sterol O-acyltransferase (SOAT) genes has opened new areas of interest …
enzymes and the sterol O-acyltransferase (SOAT) genes has opened new areas of interest …
Pharmacology of the AC AT Inhibitor Avasimibe (CI‐1011)
G Llaverías, JC Laguna… - Cardiovascular drug …, 2003 - Wiley Online Library
Avasimibe is a novel orally bioavailable ACAT inhibitor, currently under clinical development
(phase III trials). It was safe when administered to rats, dogs, and humans. In vitro studies in …
(phase III trials). It was safe when administered to rats, dogs, and humans. In vitro studies in …
ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial
MC Meuwese, E de Groot, R Duivenvoorden, MD Trip… - Jama, 2009 - jamanetwork.com
Context Inhibition of acyl coenzyme A: cholesterol acyltransferase (ACAT), an intracellular
enzyme involved in cholesterol accumulation, with pactimibe was developed to assist in the …
enzyme involved in cholesterol accumulation, with pactimibe was developed to assist in the …
The effect of L-carnitine on plasma lipoprotein (a) levels in hypercholesterolemic patients with type 2 diabetes mellitus
G Derosa, AFG Cicero, A Gaddi, A Mugellini… - Clinical …, 2003 - Elsevier
Background: A previous study has demonstrated that l-carnitine reduces plasma lipoprotein
(a)(Lp [a]) levels in patients with hypercholesterolemia. Objective: To test a tolerable Lp (a) …
(a)(Lp [a]) levels in patients with hypercholesterolemia. Objective: To test a tolerable Lp (a) …
Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia
T Sudhop, K von Bergmann - Drugs, 2002 - Springer
The benefits of lipid lowering therapy on coronary heart disease have been clearly
established in many clinical trials on primary and secondary prevention. Despite the …
established in many clinical trials on primary and secondary prevention. Despite the …
Effects of carnitine and coenzyme Q10 on lipid profile and serum levels of lipoprotein (a) in maintenance hemodialysis patients on statin therapy
M Shojaei, M Djalali, M Khatami, F Siassi… - 2011 - sid.ir
Introduction. Dyslipidemia and high serum lipoprotein (a) are among the risk factors for
cardiovascular diseases in HEMODIALYSIS patients. STATIN s as a first line of therapy in …
cardiovascular diseases in HEMODIALYSIS patients. STATIN s as a first line of therapy in …
Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs
JR Burnett, LJ Wilcox, DE Telford, SJ Kleinstiver… - Journal of lipid …, 1999 - ASBMB
An orally bioavailable acyl coenzyme A: cholesterol acyltransferase (ACAT) inhibitor,
avasimibe (CI-1011), was used to test the hypothesis that inhibition of cholesterol …
avasimibe (CI-1011), was used to test the hypothesis that inhibition of cholesterol …
Pharmacological inhibition of acyl-coenzyme A: Cholesterol acyltransferase alleviates obesity and insulin resistance in diet-induced obese mice by regulating food …
Y Zhu, SQ Kim, Y Zhang, Q Liu, KH Kim - Metabolism, 2021 - Elsevier
Background/objectives Acyl-coenzyme A: cholesterol acyltransferases (ACATs) catalyze the
formation of cholesteryl ester (CE) from free cholesterol to regulate intracellular cholesterol …
formation of cholesteryl ester (CE) from free cholesterol to regulate intracellular cholesterol …
Lipoprotein (a): an emerging cardiovascular risk factor
Lipoprotein (a) is a cholesterol-enriched lipoprotein, consisting of a covalent linkage joining
the unique and highly polymorphic apolipoprotein (a) to apolipoprotein B100, the main …
the unique and highly polymorphic apolipoprotein (a) to apolipoprotein B100, the main …
Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice?
BR Krause, HMG Princen - Atherosclerosis, 1998 - Elsevier
Hypolipidemic drugs that are efficacious in man are not always active in classical animal
models of dyslipidemia. Inhibitors of HMG-CoA reductase (statins) do not lower plasma …
models of dyslipidemia. Inhibitors of HMG-CoA reductase (statins) do not lower plasma …